natgillin/translations-raw huggingface dataset:
Copalia was also studied in an active-controlled study of 130 hypertensive patients with mean sitting diastolic blood pressure ≥110 mmHg and <120 mmHg.
Copalia je također ispitivan u aktivno kontroliranom kliničkom ispitivanju sa 130 hipertenzivnih bolesnika sa srednjom vrijednošću dijastoličkog krvnog tlaka u sjedećem položaju ≥110 mmHg i <120 mmHg.
The amlodipine component of Copalia inhibits the transmembrane entry of calcium ions into cardiac and vascular smooth muscle.
Amlodipinska komponenta Copalie inhibira transmembranski ulaz iona kalcija u srčani mišić i glatki mišić krvnih žila.
If hypotension occurs with Copalia, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline.
Ako se uz Copaliu pojavi hipotenzija, bolesnika treba poleći na leđa i po potrebi, mu dati intravensku infuziju fiziološke otopine.
Adverse reactions previously reported with one of the individual components (amlodipine or valsartan) may be potential adverse reactions with Copalia as well, even if not observed in clinical trials or during the post-marketing period.
Dodatne informacije o pojedinačnim komponentama Nuspojave koje su ranije prijavljene s jednom od pojedinačnih komponenti (amlodipinom ili valsartanom) mogu biti i moguće nuspojave Copalie, iako nisu uočene u kliničkim ispitivanjima ili nakon stavljanja lijeka u promet.
• Concomitant use of Copalia with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
• Istodobna primjena Copalie s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR <60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
if you have severe liver problems or bile problems such as biliary cirrhosis or cholestasis.
ako imate teške probleme s jetrom ili probleme sa žuči, poput bilijarne ciroze ili kolestaze.
If any of the above applies to you, do not take Copalia and talk to your doctor.
Ako se bilo što od navedenog odnosi na Vas, nemojte uzeti Copaliu i obavijestite svog liječnika.
Frequency Copalia Amlodipine Valsartan
Učestalost Copalia Amlodipin Valsartan
If any of these apply to you, tell your doctor before taking Copalia.
Ako se bilo što od navedenog odnosi na Vas, obavijestite svog liječnika prije uzimanja Copalie.
Following oral administration of Copalia, peak plasma concentrations of valsartan and amlodipine are reached in 3 and 6-8 hours, respectively.
Nakon peroralne primjene Copalie, vršne koncentracije amlodipina i valsartana u plazmi postižu se u 3 odnosno 6-8 sati.
Side effects reported with amlodipine or valsartan alone and either not observed with Copalia or observed with a higher frequency than with Copalia:
Prijavljene nuspojave s amlodipinom ili valsartanom primjenjenima samostalno ili uopće nisu opažene s Copaliom ili su opažene s većom učestalošću nego s Copaliom:
ACE inhibitors or aliskiren (see also information under the headings “Do not take Copalia” and “Warnings and precautions”); diuretics (a type of medicine also called “water tablets” which increases the amount of urine you produce); lithium (a medicine used to treat some types of depression); potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels; certain types of painkillers called non-steroidal anti-inflammatory medicines (NSAIDs) or selective cyclooxygenase-2 inhibitors (COX-2 inhibitors).
ACE inhibitori ili aliskiren (vidjeti također informacije pod naslovom „Nemojte uzimati Copaliu“ i „Upozorenja i mjere opreza“); diuretici (vrsta lijeka koja se naziva i „tablete za mokrenje“ koje povećavaju količinu mokraće koju proizvodite); litij (lijek koji se koristi za liječenje nekih vrsta depresije); diuretici koji štede kalij, nadomjesci kalija, zamjene za sol koje sadrže kalij i ostale tvari koje mogu povećati razinu kalija; određene vrste lijekova protiv bolova koji se nazivaju nesteoridni protuupalni lijekovi (NSAILi) ili selektivnim inhibitorima ciklooksigenaze-2 (COX-2 inhibitori).
There are no clinical studies on fertility with Copalia.
Ne postoje klinička ispitivanja djelovanja Copalie na plodnost.
Multipack: 280 (4 packs of 70) film-coated tablets Multipack: 280 (20 packs of 14) film-coated tablets
Višestruko pakovanje: 280 (4 pakiranja od 70) filmom obloženih tableta Višestruko pakovanje: 280 (20 pakiranja od 14) filmom obloženih tableta
if you are taking any of the following medicines used to treat high blood pressure:
ako uzimate bilo koji od lijekova navedenih u nastavku, koji se koriste za liječenje visokog krvnog tlaka:
Talk to your doctor before taking Copalia: if you have been sick (vomiting or diarrhoea).
Obratite se svom liječniku prije nego uzmete Copaliu: ako ste bili bolesni (povraćanje ili proljev).
Hepatic impairment Copalia is contraindicated in patients with severe hepatic impairment (see section 4.3).
Oštećenje jetre Copalia je kontraindiciran u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
How to take Copalia
Kako uzimati Copaliu
In this study (baseline blood pressure 171/113 mmHg), a Copalia regimen of 5 mg/160 mg titrated to 10 mg/160 mg reduced sitting blood pressure by 36/29 mmHg as compared to 32/28 mmHg with a regimen of lisinopril/hydrochlorothiazide 10 mg/12.5 mg titrated to 20 mg/12.5 mg.
U tom ispitivanju (početni krvni tlak 171/113 mmHg), liječenje Copaliom 5 mg/160 mg titriranim do 10 mg/160 mg snizilo je krvni tlak u sjedećem položaju za 36/29 mmHg, u usporedbi s 32/28 mmHg kod liječenja lizinoprilom/hidroklorotiazidom 10 mg/12,5 mg titriranim do 20 mg/12,5 mg.
Copalia should be discontinued immediately in patients who develop angioedema and should not be re-administered.
Bolesnici u kojih se razvije angioedem trebaju odmah prekinuti primjenu Copalie i više ga ne smiju ponovo uzimati.
Copalia is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.
Copalia je indiciran u odraslih osoba čiji krvni tlak nije odgovarajuće kontroliran monoterapijom amlodipinom ili valsartanom.
Copalia is used to treat high blood pressure in adults whose blood pressure is not controlled enough with either amlodipine or valsartan on its own.
Copalia se primjenjuje za liječenje povišenog krvnog tlaka u odraslih osoba čiji krvni tlak nije dovoljno kontroliran bilo samo amlodipinom ili samo valsartanom.
When switching eligible elderly hypertensive patients (see section 4.1) to amlodipine or Copalia, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.
Prilikom prebacivanja starijih hipertenzivnih bolesnika koji ispunjavaju uvjete za liječenje (vidjeti dio 4.1) na amlodipin ili Copaliu, treba se koristiti najniža dostupna doza amlodipina u monoterapiji ili amlodipina kao komponente.
Excessive hypotension was seen in 0.4% of patients with uncomplicated hypertension treated with Copalia in placebo-controlled studies.
U placebo-kontroliranim ispitivanjima, u 0,4% bolesnika s nekompliciranom hipertenzijom liječenih Copaliom viđena je izražena hipotenzija.
How to store Copalia
Kako čuvati Copaliu
Copalia 5 mg/80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone.
Copalia 5 mg/80 mg se može primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 5 mg ili valsartanom 80 mg.
Particular caution should be exercised when administering Copalia to patients with mild to moderate hepatic impairment or biliary obstructive disorders.
Nužan je poseban oprez kod primjene Copalie bolesnicima s blagim do umjerenim oštećenjem jetre ili opstruktivnim poremećajima žučnog sustava.
Caution should be exercised when administering Copalia to patients with hepatic impairment or biliary obstructive disorders (see section 4.4).
Nužan je oprez kod primjene Copalie bolesnicima s oštećenjem jetre ili opstruktivnim bolestima žučnog sustava (vidjeti dio 4.4).
When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to amlodipine or Copalia, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used.
Prilikom prebacivanja hipertenzivnih bolesnika koji ispunjavaju uvjete za liječenje (vidjeti dio 4.1) s oštećenjem jetre na amlodipin ili Copaliu, treba se koristiti najniža dostupna doza amlodipina u monoterapiji ili amlodipina kao komponente.
Copalia 5 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone.
Copalia 5 mg/160 mg se može primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 5 mg ili valsartanom 160 mg.
This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active substance amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Copalia.
Grejp i sok od grejpa u nekih bolesnika može dovesti do povećanja razina djelatne tvari amlodipina u krvi, što može uzrokovati neočekivano pojačani učinak na snižavanje krvnog tlaka.
No dosage adjustment of Copalia is required for patients with mild to moderate renal impairment (GFR >30 ml/min/1.73 m2).
U bolesnika s blagim do umjerenim oštećenjem bubrega (GFR >30 ml/min/1,73 m2) doziranje Copalie nije potrebno prilagođavati.
Copalia 10 mg/160 mg tablets are oval and light yellow with “NVR” on one side and “UIC” on the other side.
Copalia 10 mg/160 mg tablete su ovalne, svijetložute tablete, s oznakom „NVR“ na jednoj strani i „UIC“ na drugoj strani.
Copalia 5 mg/80 mg film-coated tablets Copalia 5 mg/160 mg film-coated tablets Copalia 10 mg/160 mg film-coated tablets
Copalia 5 mg/80 mg filmom obložene tablete Copalia 5 mg/160 mg filmom obložene tablete Copalia 10 mg/160 mg filmom obložene tablete
Copalia 5 mg/160 mg tablets are oval and dark yellow “NVR” on one side and “ECE” on the other side.
Copalia 5 mg/160 mg tablete su ovalne, tamnožute tablete, s oznakom „NVR“ na jednoj strani i „ECE“ na drugoj strani.
Copalia 5 mg/80 mg film-coated tablets Copalia 5 mg/160 mg film-coated tablets Copalia 10 mg/160 mg film-coated tablets amlodipine/valsartan
Copalia 5 mg/80 mg filmom obložene tablete Copalia 5 mg/160 mg filmom obložene tablete Copalia 10 mg/160 mg filmom obložene tablete amlodipin/valsartan
Copalia 5 mg/80 mg film-coated tablets
Copalia 5 mg/80 mg filmom obložene tablete
Copalia 10 mg/160 mg film-coated tablets
Copalia 10 mg/160 mg filmom obložene tablete
EU/1/06/372/035 280 film-coated tablets (4x70) EU/1/06/372/038 280 film-coated tablets (20x14)
EU/1/06/372/035 280 filmom obloženih tableta (4x70) EU/1/06/372/038 280 filmom obloženih tableta (20x14)
Grapefruit and grapefruit juice should not be consumed by people who are taking Copalia.
Bolesnici koji uzimaju Copaliu ne smiju konzumirati grejp ili sok od grejpa.
EU/1/06/372/036 280 film-coated tablets (4x70) EU/1/06/372/039 280 film-coated tablets (20x14)
EU/1/06/372/036 280 filmom obloženih tableta (4x70) EU/1/06/372/039 280 filmom obloženih tableta (20x14)
Copalia 5 mg/160 mg film-coated tablets
Copalia 5 mg/160 mg filmom obložene tablete
EU/1/06/372/034 280 film-coated tablets (4x70) EU/1/06/372/037 280 film-coated tablets (20x14)
EU/1/06/372/034 280 filmom obloženih tableta (4x70) EU/1/06/372/037 280 filmom obloženih tableta (20x14)
Copalia 5 mg/80 mg film-coated tablets amlodipine/valsartan
Copalia 5 mg/80 mg filmom obložene tablete amlodipin/valsartan
Copalia 10 mg/160 mg film-coated tablets amlodipine/valsartan
Copalia 10 mg/160 mg filmom obložene tablete amlodipin/valsartan
Copalia 5 mg/160 mg film-coated tablets amlodipine/valsartan
Copalia 5 mg/160 mg filmom obložene tablete amlodipin/valsartan
EU/1/06/372/017 7 film-coated tablets EU/1/06/372/018 14 film-coated tablets EU/1/06/372/019 28 film-coated tablets EU/1/06/372/020 30 film-coated tablets EU/1/06/372/021 56 film-coated tablets EU/1/06/372/022 90 film-coated tablets EU/1/06/372/023 98 film-coated tablets EU/1/06/372/024 280 film-coated tablets EU/1/06/372/031 56x1 film-coated tablet (unit dose) EU/1/06/372/032 98x1 film-coated tablet (unit dose) EU/1/06/372/033 280x1 film-coated tablet (unit dose)
EU/1/06/372/017 7 filmom obloženih tableta EU/1/06/372/018 14 filmom obloženih tableta EU/1/06/372/019 28 filmom obloženih tableta EU/1/06/372/020 30 filmom obloženih tableta EU/1/06/372/021 56 filmom obloženih tableta EU/1/06/372/022 90 filmom obloženih tableta EU/1/06/372/023 98 filmom obloženih tableta EU/1/06/372/024 280 filmom obloženih tableta EU/1/06/372/031 56x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/032 98x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/033 280x1 filmom obloženih tableta (jedinična doza)
EU/1/06/372/001 7 film-coated tablets EU/1/06/372/002 14 film-coated tablets EU/1/06/372/003 28 film-coated tablets EU/1/06/372/004 30 film-coated tablets EU/1/06/372/005 56 film-coated tablets EU/1/06/372/006 90 film-coated tablets EU/1/06/372/007 98 film-coated tablets EU/1/06/372/008 280 film-coated tablets EU/1/06/372/025 56x1 film-coated tablet (unit dose) EU/1/06/372/026 98x1 film-coated tablet (unit dose) EU/1/06/372/027 280x1 film-coated tablet (unit dose)
EU/1/06/372/001 7 filmom obloženih tableta EU/1/06/372/002 14 filmom obloženih tableta EU/1/06/372/003 28 filmom obloženih tableta EU/1/06/372/004 30 filmom obloženih tableta EU/1/06/372/005 56 filmom obloženih tableta EU/1/06/372/006 90 filmom obloženih tableta EU/1/06/372/007 98 filmom obloženih tableta EU/1/06/372/008 280 filmom obloženih tableta EU/1/06/372/025 56x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/026 98x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/027 280x1 filmom obloženih tableta (jedinična doza)
What Copalia looks like and contents of the pack Copalia 5 mg/80 mg tablets are round and dark yellow with “NVR” on one side and “NV” on the other side.
Copalia 5 mg/80 mg tablete su okrugle, tamnožute tablete, s oznakom „NVR“ na jednoj strani i „NV“ na drugoj strani.
EU/1/06/372/009 7 film-coated tablets EU/1/06/372/010 14 film-coated tablets EU/1/06/372/011 28 film-coated tablets EU/1/06/372/012 30 film-coated tablets EU/1/06/372/013 56 film-coated tablets EU/1/06/372/014 90 film-coated tablets EU/1/06/372/015 98 film-coated tablets EU/1/06/372/016 280 film-coated tablets EU/1/06/372/028 56x1 film-coated tablet (unit dose) EU/1/06/372/029 98x1 film-coated tablet (unit dose) EU/1/06/372/030 280x1 film-coated tablet (unit dose)
EU/1/06/372/009 7 filmom obloženih tableta EU/1/06/372/010 14 filmom obloženih tableta EU/1/06/372/011 28 filmom obloženih tableta EU/1/06/372/012 30 filmom obloženih tableta EU/1/06/372/013 56 filmom obloženih tableta EU/1/06/372/014 90 filmom obloženih tableta EU/1/06/372/015 98 filmom obloženih tableta EU/1/06/372/016 280 filmom obloženih tableta EU/1/06/372/028 56x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/029 98x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/030 280x1 filmom obloženih tableta (jedinična doza)
if you have narrowing of the aortic valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body).
(Također je bolje izbjegavati Copaliu u ranoj trudnoći, vidjeti dio Trudnoća). ako imate jako nizak krvni tlak (hipotenzija). ako imate suženje aortnog zaliska (stenoza aorte) ili kardiogeni šok (stanje u kojem Vaše srce ne može opskrbiti tijelo dovoljnom količinom krvi). ako patite od zatajivanja srca nakon srčanog udara.
Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00
Slovenská republika Novartis Slovakia r.o. Tel: +421 2 5542 5439
The active substances of Copalia are amlodipine (as amlodipine besylate) and valsartan.
Djelatne tvari u Copalii su amlodipin (u obliku amlodipinbesilata) i valsartan.
Novartis Pharma B.V. Tel: +31 26 37 82 111
Vifor Pharma España, S.L. Tel: +34 902 12 11 11
The full EPAR for Lifmior can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjeloviti EPAR za lijek Lifmior nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
In adults, the usual recommended dose is 25 mg twice a week or 50 mg once a week.
Uobičajena preporučena doza za odrasle jest 25 mg dvaput tjedno ili 50 mg jednom tjedno.
Lifmior is identical to Enbrel, which has been authorised in the EU since 3 February 2000.
Lifmior je jednak lijeku Enbrel, koji je odobren u EU-u 3. veljače 2000. godine.
This is a summary of the European public assessment report (EPAR) for Lifmior.
Ovo je sažetak Europskog javnog izvješća o procjeni (EPAR) lijeka Lifmior.
In rheumatoid arthritis, five studies have been carried out involving around 2,200 patients.
U vezi s reumatoidnim artritisom provedeno je 5 ispitivanja u kojima je sudjelovalo približno 2 200 bolesnika.
This compared with around a quarter of the patients receiving placebo.
To je bio slučaj u usporedbi s četvrtinom bolesnika koji su primili placebo.
The patient or carer can give the injection if they have been trained appropriately.
Bolesnik ili njegovatelj mogu dati injekciju ako su odgovarajuće osposobljeni.
What measures are being taken to ensure the safe and effective use of Lifmior?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Lifmior?
By blocking TNF, etanercept reduces the inflammation and other symptoms of the diseases.
Blokiranjem TNF-a etanercept ublažuje upalu i druge simptome bolesti.
Lifmior is an anti-inflammatory medicine for treating the following diseases:
Lifmior je protuupalni lijek za liječenje sljedećih bolesti:
In children, the dose will depend on body weight.
Doza za djecu utvrdit će se u skladu s tjelesnom masom.
Lifmior must not be used in patients who have or are at risk of sepsis (when bacteria and toxins circulate in the blood and start to damage the organs), or in patients with infections.
Lifmior se ne smije primjenjivati u bolesnika koji imaju sepsu ili u kojih postoji rizik od sepse (kada bakterije i toksini cirkuliraju krvotokom i počnu oštećivati organe) ili u bolesnika s infekcijama.
Other information about Lifmior
Ostale informacije o lijeku Lifmior
Why is Lifmior approved?
Zašto je Lifmior odobren?
Lifmior is mostly used when these conditions are severe or moderately severe, or when other treatments have not worked well enough.
Lifmior se uglavnom primjenjuje kada su navedene bolesti teške ili umjereno teške ili kada liječenje nije bilo dovoljno uspješno.
Further studies have been carried out in over 2,300 patients with other inflammatory diseases (juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and axial spondyloarthritis).
Provedena su daljnja ispitivanja na više od 2 300 bolesnika oboljelih od drugih upalnih bolesti (juvenilnog idiopatskog artritisa, psorijatičnog artritisa, ankilozantnog spondilitisa, plak psorijaze i aksijalnog spondiloartritisa).
In a fourth study of rheumatoid arthritis patients who had not taken methotrexate before, those receiving 25 mg Lifmior twice a week had less joint damage than those taking methotrexate alone after 12 and 24 months.
U četvrtom ispitivanju na bolesnicima oboljelima od reumatoidnog artritisa koji prethodno nisu uzimali metotreksat, bolesnici koji su dvaput tjedno primali 25 mg lijeka Lifmior imali su manja oštećenja zglobova u bolesnika koji su uzimali samo metotreksat nakon 12 i 24 mjeseca.
The CHMP therefore concluded that Lifmior's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za lijekove za humanu uporabu (CHMP) stoga je zaključio da koristi od lijeka Lifmior nadmašuju rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
What is Lifmior and what is it used for?
Što je Lifmior i za što se uzima?
It is not intended to provide practical advice on how to use Lifmior.
Svrha sažetka nije pružiti praktične savjete o primjeni lijeka Lifmior.
The most common side effects with Lifmior (seen in more than 1 patient in 10) are injection site reactions (including bleeding, bruising, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections).
Najčešće su nuspojave lijeka Lifmior (uočene u više od 1 na 10 osoba) reakcije na mjestu ubrizgavanja injekcije (uključujući krvarenje, nastanak modrica, crvenilo, svrbež, bol i oticanje) i infekcije (uključujući prehladu te infekcije pluća, mjehura i kože).
The company that markets Lifmior will provide educational material for doctors expected to prescribe the product to teach patients how to use the pre-filled pen correctly and a special alert card for patients so they can recognise serious side effects and know when to seek urgent attention from their doctor.
Tvrtka koja stavlja lijek Lifmior u promet dostavit će obrazovne materijale liječnicima koji će propisati navedeni proizvod kako bi mogli podučiti bolesnike kako ispravno upotrebljavati napunjenu brizgalicu te posebnu karticu s upozorenjima za bolesnike kako bi mogli prepoznati teške nuspojave i znati kada zatražiti hitnu liječničku pomoć.
What is the risk associated with Lifmior?
Koji su rizici povezani s lijekom Lifmior?
Three of these studies in patients who had taken arthritis medicines in the past showed about two-thirds of the patients who received Lifmior had a reduction in symptoms of 20% or more after three months based on a standard rating score (ACR 20).
Tri navedena ispitivanja na bolesnicima koji su u prošlosti uzimali lijekove protiv artritisa pokazala su, u dvije trećine bolesnika koji su primili Lifmior, smanjenje simptoma za 20 % ili više nakon tri mjeseca na temelju standardne skale rezultata (ACR 20).
It contains the active substance etanercept.
Sadrži djelatnu tvar etanercept.
Patients developing a serious infection should stop Lifmior treatment.
Bolesnici u kojih je došlo do teških infekcija trebaju prestati uzimati lijek Lifmior.
Lifmior is given as an injection under the skin.
Lifmior se daje kao potkožna injekcija.
Several studies have shown that Lifmior is more effective at reducing symptoms of inflammatory conditions than placebo (a dummy treatment) or a comparator medicine.
Nekoliko ispitivanja pokazalo je da je lijek Lifmior djelotvorniji u smanjenju simptoma upalnih bolesti od placeba (prividnog liječenja) ili usporednog lijeka.
These studies also showed that Lifmior produced a greater improvement in symptoms than placebo after three to four months using various standard rating scores such as ACR, ASAS and PASI.
Ta su ispitivanja također pokazala da je lijek Lifmior doprinio znatnom smanjenju simptoma u odnosu na placebo nakon tri do četiri mjeseca na temelju različitih standardnih skala rezultata kao što su ACR, ASAS i PASI.
Treatment is started and supervised by specialised doctors with experience in diagnosing and treating the diseases Lifmior is used for.
Liječenje započinju i nadgledaju liječnici specijalisti s iskustvom u dijagnosticiranju i liječenju bolesti za koje se lijek Lifmior primjenjuje.
Lifmior is effective at reducing symptoms in several inflammatory conditions and its side effects are considered manageable.
Lifmior je učinkovit u smanjenju simptoma nekoliko upalnih bolesti i njegove je nuspojave moguće kontrolirati.
The active substance in Lifmior, etanercept, is a protein that has been designed to block the activity of a substance called tumour necrosis factor (TNF).
Etanercept, djelatna tvar u lijeku Lifmior, je protein namijenjen blokiranju djelovanja tvari naziva faktor tumorske nekroze (TNF).
A fifth study showed that Lifmior on its own or in combination with methotrexate was more effective than methotrexate alone.
Peto ispitivanje pokazalo je da je uzimanje lijeka Lifmior kao monoterapija ili u kombinaciji s metotreksatom djelotvornije od uzimanja metotreksata kao monoterapije.
• certain forms of juvenile idiopathic arthritis (inflammation of joints in children and adolescents)
• određenih oblika juvenilnog idiopatskog artritisa (upale zglobova u djece i adolescenata)